STOCK TITAN

LB Pharmaceuticals: Trails Edge reports 3.6% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

LB Pharmaceuticals Inc. (LBRX) common stock was reported as beneficially owned by Trails Edge Biotechnology Master Fund, LP, which directly held 1,149,240 shares as of September 30, 2026. That stake represented 3.6% of the class. The fund’s investment manager, Trails Edge Capital Partners, LP, and Ortav Yehudai, the manager’s chief investment officer, may also be deemed beneficial owners of the same shares. Each filer reported sole voting and dispositive power over 1,149,240 shares and zero shared power.

Shares beneficially owned 1,149,240 shares Directly held by Trails Edge Biotechnology Master Fund as of September 30, 2026; also attributed as beneficial ownership to the other filers.
Ownership percentage 3.6% Percentage of LB Pharmaceuticals common stock beneficially owned.
Shares issued and outstanding 32,259,175 shares As of August 5, 2026; used as the basis for the ownership percentages.
beneficially own regulatory
"may be deemed to beneficially own an aggregate of 1,149,240 shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
sole voting power regulatory
"Sole Voting Power 1,149,240.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power regulatory
"Sole Dispositive Power 1,149,240.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LBRX shares did Trails Edge Biotechnology Master Fund report owning?

Trails Edge Biotechnology Master Fund, LP directly held 1,149,240 LB Pharmaceuticals common shares as of September 30, 2026. Its investment manager and the manager’s chief investment officer may also be deemed beneficial owners of that same stake.

What share count was used to calculate the 3.6% LBRX ownership stake?

The calculation was based on 32,259,175 shares issued and outstanding as of August 5, 2026, as reported in LB Pharmaceuticals’ quarterly report filed August 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





50180M108

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4 for additional information.


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4 for additional information.


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4 for additional information.


SCHEDULE 13G



Trails Edge Capital Partners, LP
Signature:By: Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai
Name/Title:Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Date:11/16/2026
Trails Edge Biotechnology Master Fund, LP
Signature:By: Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai
Name/Title:Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC
Date:11/16/2026
Ortav Yehudai
Signature:/s/ Ortav Yehudai
Name/Title:Ortav Yehudai / Individual
Date:11/16/2026
Exhibit Information

Exhibit 1 - Joint Filing Agreement dated as of December 31, 2025, by and between Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on December 31, 2025).

Keep reading